1 recruiting, 1 terminated. 2 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Recruiting 1, Terminated 1 |
| Phase 2 | 1 | Recruiting 1 |
Follow Accent Therapeutics: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer ATX-295, ATX-295 and bevacizumab (or biosimilar) - Advanced Solid Tumors, Breast Cancer Recurrent | Phase 1 / Phase 2 | Recruiting | Accent Therapeutics | 218 | 2025-03-21 | 2026-10-13 |
| First-in-Human Study of ATX-559, an Oral Inhibitor of DHX9, in Patients With Advanced or Metastatic Solid Tumors, and Molecularly Defined Cancers ATX-559 - Advanced Solid Tumors, Breast Cancer Recurrent | Phase 1 | Terminated | Accent Therapeutics | 17 | 2024-10-11 | 2026-02-24 |
Colonic Neoplasms (1) · Endometrial Neoplasms (1) · Microsatellite Instability (1) · Ovarian Neoplasms (1) · Rectal Neoplasms (1) · Triple Negative Breast Neoplasms (1)
Bevacizumab (1) · Biosimilar Pharmaceuticals (1)
United States (2)
Gozde Colak, PhD (1)